Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.

Our pipeline


The panNASH initiative contributes to a better understanding of NASH and the specific importance of panPPAR agonism in the treatment of this disease.

Pannash Website


A royalty bearing partnership in place with Abbvie validating our approach and the potential of our discovery engine.

Our partnerships

Inventiva in Numbers


Partnership (Abbvie)


Innovative Clinical Programmes


People in our Scientific Team


Patent Families

A Library of



Welcome to Inventiva Pharma

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

By leveraging these assets and expertise, we are advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

About Inventiva

Financial Information

Upcoming Events

Q2 2021 financial information – Revenues and cash

28th July 2021
(after U.S market closure)

H1 2021 financial results

20th September 2021
(after U.S market closure)

Share Information

€11.8 -1.17%

Last update: May 14, 2021 at 09:45 CET

Open: €11.96
Previous close: €11.94

Day High: €11.98
Day Low: €11.8

Therapeutic Areas

Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.

Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of this disease: inflammation, steatosis, ballooning, and more importantly fibrosis.

Lanifibranor completed a phase IIb study. After only 6 months of treatment, lanifibranor achieved statistically significance in both regulatory endpoints required by FDA and EMA: resolution of NASH without worsening of fibrosis and reduction in fibrosis without worsening of NASH. These results, in addition to an excellent safety profile, clearly differentiate lanifibranor from any other treatment in development for NASH. For more details of the headline results see the results presentation.

Mucopolysaccharidosis (MPS)

MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.

Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.

In the recently completed iMProveS phase IIa study, odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.

Phase IIb trial in NASH, enrollment completed

Phase IIa in adult MPSVI patients, completed

Inventiva Pharma

50 Rue de Dijon
21121 Daix, France
Email :
Call : +33 (0)3 80 44 75 00